There remains a need to create a host active specific immune response, generating an army of tumor reactive T-cells that can attack a patient’s disease alone and improve the outcomes for patients on therapies that manipulate T cells in the adjuvant and metastatic settings.
In a pre-specified interim analysis, data were recently presented from prospective, randomized, double-blinded, placebo-controlled Phase 2b trial evaluating TLPLDC therapy compared to placebo in patients with resected Stage III and IV melanoma.
ELIOS has forged partnerships with leading research institutions around the United States. Our goal is to continue to expand the experience and effectiveness of our novel approach to personalized therapeutic cancer vaccines.
(Trademarks listed above, registered or unregistered, are the property of their respective owners.)